STOCK TITAN

CareDx, Inc. - CDNA STOCK NEWS

Welcome to our dedicated page for CareDx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on CareDx stock.

CareDx, Inc. (NASDAQ: CDNA) is at the forefront of transforming transplant patient care through its innovative surveillance management solutions. Dedicated to improving the lives of organ transplant patients, CareDx leverages the latest in genomics and bioinformatics technology combined with rigorous clinical evidence derived from trials and registries.

CareDx offers a suite of precision medicine solutions aimed at enhancing both pre- and post-transplant care. One of its flagship products, AlloSure®, is the first and only non-invasive blood test that directly measures allograft injury. This next-generation sequencing (NGS) based test detects donor-derived cell-free DNA (dd-cfDNA), providing clinicians with a powerful tool to identify organ injury and the probability of active rejection, particularly in kidney transplant patients.

The company's portfolio also includes AlloMap Heart, AlloSure Heart, and AlloSure Lung, which are dd-cfDNA solutions designed for heart and lung transplant recipients. These products underscore CareDx’s commitment to offering clinically differentiated, high-value healthcare solutions that span the entire transplant journey.

CareDx generates the majority of its revenue from the United States, with a significant portion coming from its testing services. Its product suite not only addresses the critical needs of transplant patients but also supports healthcare providers in delivering better patient outcomes through genomics-based information.

Recent achievements include the continued expansion of their product line and partnerships with leading healthcare institutions to further validate and implement their innovative diagnostic solutions. These efforts position CareDx as a leader in the field of transplant diagnostics and surveillance.

Rhea-AI Summary

CareDx, Inc. (NASDAQ: CDNA) has announced it will report its financial results for the fourth quarter and full year 2022 on February 27, 2023, after market closure. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET for management to discuss the results. Interested parties can join the call by dialing 1-877-704-4453 (domestic) or 1-201-389-0920 (international), referencing Conference ID: 13736063. CareDx specializes in precision medicine solutions for transplant patients, delivering testing services and products throughout the patient journey.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.09%
Tags
conferences earnings
-
Rhea-AI Summary

CareDx, a precision medicine company, is set to present its innovative solutions for cellular transplant and therapy at the 2023 Tandem Meetings from February 15-19 in Orlando, Florida. CEO Reg Seeto emphasized the importance of these advancements in cell therapy monitoring and digital health. Notable presentations include AutoCell™, a high-sensitivity solution for CAR-T cell monitoring, and various digital health solutions aimed at improving patient care across transplant centers. CareDx's offerings include workflow management, medication adherence solutions, and remote monitoring tools designed for effective patient engagement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
-
Rhea-AI Summary

CareDx, Inc. (CDNA) announced the publication of a guide in the Journal of the American College of Cardiology to assist clinicians in transitioning from invasive endomyocardial biopsies (EMB) to non-invasive monitoring for heart transplant rejection using AlloMap GEP and AlloSure dd-cfDNA. The guide highlights the clinical utility of these non-invasive tests, emphasizing their effectiveness in rejection surveillance. CareDx's HeartCare services are now utilized in over 90% of U.S. heart transplant centers, reflecting a growing trend towards non-invasive practices in heart transplant monitoring.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
Rhea-AI Summary

CareDx (NASDAQ: CDNA) announced its participation as a Distinguished Founder’s Circle Sponsor at the 23rd Annual ASTS State of the Art Winter Symposium from January 12-15, 2023, in Miami, Florida. This marks the fourth consecutive year for CareDx at this event, emphasizing their commitment to innovation in transplant patient care. The company will host a symposium on January 13 to present advancements in molecular surveillance and digital health solutions. CareDx’s products, like AlloMap and AlloSure, are widely used in transplant centers across the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.23%
Tags
none
-
Rhea-AI Summary

CareDx, Inc. (NASDAQ: CDNA) reported preliminary financial results for Q4 and full year 2022, highlighting record revenues between $81.9 million and $82.2 million, marking a 4% year-over-year growth. Cash collections reached 110% of revenue, a 10% increase, while patient test results rose by 14%. The company maintained a strong cash position of approximately $292 million with no debt. For FY 2022, revenue is expected to be between $321.3 million and $321.6 million, indicating an 8% growth. CareDx plans to focus on pipeline catalysts and increased collections in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.6%
Tags
none
-
Rhea-AI Summary

CareDx, Inc. announces that the International Society for Heart and Lung Transplantation (ISHLT) has updated its guidelines, recommending the earlier use of AlloMap Heart for heart transplant patients starting 2 months post-transplant. The new guidelines endorse donor-derived cell-free DNA (dd-cfDNA) testing for routine monitoring, promoting non-invasive methods to minimize biopsies and hospital visits. These changes reflect the clinical advancements in the last decade and are supported by significant uptake in heart transplant centers nationwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
none
Rhea-AI Summary

CareDx, Inc. (NASDAQ: CDNA) has announced a stock repurchase program authorized by its Board of Directors, allowing for up to $50 million in stock buybacks over 24 months. The program enables discretionary purchases via open market repurchases, private transactions, and trading plans. CEO Reg Seeto expressed confidence in the company's financial position and growth prospects, stating that share buybacks reflect their commitment to long-term shareholder value. The repurchases will utilize existing cash and future cash flow.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.27%
Tags
buyback
-
Rhea-AI Summary

CareDx, Inc. (Nasdaq: CDNA) announced the results of a significant study in the Transplantation Direct journal, establishing a reference baseline for using AlloSure® Lung in lung transplant patient surveillance. Conducted at Vanderbilt University Medical Center, the study involved 51 patients and defined a 73% reference change value for AlloSure dd-cfDNA levels two years post-transplant. This data underscores the clinical utility of AlloSure Lung, currently utilized by 60% of lung centers, as a vital tool amid high lung graft failure rates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
none
-
Rhea-AI Summary

CareDx, Inc. (Nasdaq: CDNA) celebrated the five-year anniversary of AlloSure, a non-invasive solution for monitoring organ transplant health. The company emphasized its leadership in transplant research, with over 100 peer-reviewed publications supporting the clinical use of AlloSure and AlloMap. Having invested more than $200 million in research over the past three years, CareDx continues to enhance transplant outcomes, addressing the significant need for accurate biomarkers in organ transplants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.1%
Tags
none
Rhea-AI Summary

CareDx, Inc. (Nasdaq: CDNA), a leader in precision medicine for transplant patients, will participate in two investor conferences. The first presentation is at the Credit Suisse 31st Annual Healthcare Conference on November 9, 2022, at 1:25 PM ET, accessible via their website. The second is at the Jefferies London Healthcare Conference on November 15, 2022, at 8:30 AM ET. CareDx aims to enhance healthcare solutions for transplant patients and caregivers through innovative testing services and digital solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.47%
Tags
conferences

FAQ

What is the current stock price of CareDx (CDNA)?

The current stock price of CareDx (CDNA) is $20.61 as of December 20, 2024.

What is the market cap of CareDx (CDNA)?

The market cap of CareDx (CDNA) is approximately 1.1B.

What does CareDx, Inc. specialize in?

CareDx, Inc. specializes in precision medicine and surveillance management solutions aimed at improving the lives of organ transplant patients.

What is AlloSure®?

AlloSure® is a non-invasive blood test that measures allograft injury and detects donor-derived cell-free DNA (dd-cfDNA) to identify organ injury in kidney transplant patients.

Which organs do CareDx's products focus on?

CareDx's products focus on kidney, heart, and lung transplants.

Where does CareDx generate most of its revenue?

CareDx generates the majority of its revenue from the United States, primarily through its testing services.

What are some key products offered by CareDx?

Key products include AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung, all of which are dd-cfDNA solutions.

How does CareDx support transplant patients?

CareDx supports transplant patients by offering non-invasive diagnostic tests that help in monitoring and managing organ transplant health.

What technology does CareDx use in its diagnostics?

CareDx uses genomics and bioinformatics technology, specifically next-generation sequencing (NGS) to develop its diagnostic tests.

Does CareDx collaborate with other healthcare institutions?

Yes, CareDx partners with leading healthcare institutions to validate and implement their diagnostic solutions.

What kind of clinical evidence does CareDx generate?

CareDx generates high-quality clinical evidence through trials and registries to support the efficacy of its products.

What makes CareDx a leader in transplant diagnostics?

CareDx's combination of innovative diagnostic solutions, clinical evidence, and partnerships positions it as a leader in transplant diagnostics and surveillance.

CareDx, Inc.

Nasdaq:CDNA

CDNA Rankings

CDNA Stock Data

1.11B
51.79M
3.45%
96.05%
5.73%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
BRISBANE